Iressa Related Clinical Trials
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer [Active, not recruiting]
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Active, not recruiting]
Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment [Active, not recruiting]
Open-Label Extension of Other SZ1839 (Iressa) Trials [Completed]
First Line IRESSAâ„¢ Versus Carboplatin/Paclitaxel in Asia [Active, not recruiting]
IRESSAâ„¢ (Gefitinib) in Breast Cancer Patients [Completed]
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer [Completed]
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma [Active, not recruiting]
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer [Active, not recruiting]
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer [Completed]
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer [Active, not recruiting]
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study [Completed]
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer [Active, not recruiting]
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC [Active, not recruiting]
Iressa as Second Line Therapy in Advanced NSCLC-Asia [Completed]
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) [Active, not recruiting]
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer [Active, not recruiting]
Hydroxychloroquine and Gefitinib to Treat Lung Cancer [Recruiting]
Gefitinib 500mg Versus 250mg in Patients With Non-Small Cell Lung Cancer (NSCLC) With Stable Disease After a Month Treatment of Gefitinib 250mg [Recruiting]
Ph II Early BC Pre-Surgical Biologic Study [Completed]
Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer [Recruiting]
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone [Recruiting]
Trial of Iressa in Prostate Cancer Patients [Completed]
Iressa Study in Patients With Salivary Gland Cancer [Active, not recruiting]
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer [Terminated]
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment [Recruiting]
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma [Completed]
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients [Active, not recruiting]
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone [Recruiting]
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer [Terminated]
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy [Recruiting]
JS 0414 A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma [Recruiting]
Phase II Iressa Versus Vinorelbine (INVITE) [Completed]
Open Label Trial to Assess Iressa in Prostate Cancer Patients [Completed]
First Line Gefitinib by FDG-PET Metabolic Response [Recruiting]
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck [No longer recruiting]
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma [Active, not recruiting]
ZD1839 (Iressaâ„¢) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer [Completed]
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) [Completed]
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP) [Recruiting]
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) [Recruiting]
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer [Active, not recruiting]
Iressa v BSC (Best Supportive Care) in First Line NSCLC
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis [Recruiting]
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC) [Recruiting]
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR [Terminated]
Iressa Versus Docetaxel (Taxotere) [Completed]
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors [Recruiting]
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) [Recruiting]
ZD1839 (Iressaâ„¢) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer [Completed]
Iressa Follow-up Trial [Recruiting]
Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer [Active, not recruiting]
Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations [Recruiting]
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer [Active, not recruiting]
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Active, not recruiting]
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Followed by Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung [Completed]
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer [Active, not recruiting]
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Recruiting]
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers [Recruiting]
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer [Completed]
Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research [Completed]
Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer [Active, not recruiting]
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy [Recruiting]
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer [Completed]
Radiotherapy, Combination Chemotherapy, and Gefitinib Before and After Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer [Active, not recruiting]
Gefitinib in Treating Patients With Cervical Cancer [Completed]
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas [Terminated]
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer [No longer recruiting]
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer [No longer recruiting]
Phase II Iressa & Carbo/Gem in NSCLC [Active, not recruiting]
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer [Active, not recruiting]
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck [Completed]
Cisplatin, Fluorouracil, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer [Active, not recruiting]
A Phase II Exploratory, Multicentre, Open-Label, Non-Comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme [Completed]
Post-Operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas [Recruiting]
Trial Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer [Completed]
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer [Completed]
Study to Evaluate SCH 900105 in Combination With Gefitinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) (Study P06162AM1) [Recruiting]
ARCHER-1050: A Study Of PF-00299804 (Dacomitinib) Vs. Gefitinib In 1st-Line Treatment Of Advanced NSCLC. [Not yet recruiting]
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 [Recruiting]
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation [Recruiting]
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Combination Casodex® and Iressaâ„¢ in Locally Advanced Prostate Cancer [Completed]
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) [Recruiting]
Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer [Recruiting]
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer [Completed]
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer [No longer recruiting]
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer [Active, not recruiting]
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non Small Cell Lung Cancer [Recruiting]
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery [Terminated]
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer [Recruiting]
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer [No longer recruiting]
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-Small-Cell Lung Cancer [No longer recruiting]
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery [Recruiting]
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma [Recruiting]
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) [Active, not recruiting]
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study [Completed]
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas [Active, not recruiting]
First-Line Gefitinib vs.Chemotherapy for Lung Adenocarcinoma in Never Smoker [Active, not recruiting]
|
